CLNN · Clene Inc. · Investor Relations
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern. To mitigate our funding needs, we plan to raise additional funding, including exploring equity financing and offerings, debt financing, licensing or collaboration arrangements with third parties, as well as utilizing our existing at-the-market facility and potential proceeds from the exercise of outstanding warrants and stock options. These plans are subject to market conditions and reliance on third parties, and there is no assurance that effective implementation of our plans will result in the necessary funding to continue current operations. During the three and six months ended June 30, 2026, we raised $7.0 million and $13.0 million, respectively, of gross proceeds from registered direct offerings of equity securities (see Note 13 to the condensed consolidated financial statements). While we have implemented cost-saving initiatives, including delaying and reducing certain research and development programs and commercialization efforts, reducing employee compensation, and eliminating certain staff positions, we have concluded that our plans do not alleviate the substantial doubt about our ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements contained in this report are issued.”View the 10-Q filed Aug 14, 2026
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-10-19 |
Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS
NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes SALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on revolutionizing the treatment of |
| 2026-09-22 |
Clene to Present at Upcoming Investor Conferences
SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5 th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners Investor Conference Fall Event and host 1x1 investor meetings at both conferences. |
| 2026-09-21 |
Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
Investment was led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders $4 million registered direct offering was priced at market under Nasdaq rules Proceeds are expected to be |
| 2026-09-15 |
Clene Announces $4 Million Registered Direct Offering
Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders $4 million registered direct offering priced at market under Nasdaq rules Proceeds are expected to be sufficient to |
| 2026-09-03 |
Clene to Present at Upcoming September Investor Conferences
SALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the 2026 Cantor Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference and host 1x1 investor meetings at both conferences. |
| 2026-08-17 |
Clene to Present at the Emerging Growth Conference
SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the Emerging Growth Conference. Virtual Presentation Details Date: August 19, 2026 Time of Presentation: 3:10 p.m. ET Format: Corporate update A webcast of the presentation |
| 2026-08-14 |
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026 Clene announces survival and functional benefit in CNM-Au8-treated patients whose NfL declined or stabilized SALT LAKE CITY, Aug. |
| 2026-08-10 |
Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval
Survival benefit is concentrated in participants with NfL biomarker response: CNM-Au8 ® -treated patients whose NfL declined or stabilized lived significantly longer than concurrently randomized controls Functional benefit concentrated in participants with NfL biomarker response: CNM-Au8-treated |
| 2026-07-29 |
Clene to Present at The Canaccord 46th Annual Growth Conference
SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, |
| 2026-05-14 |
Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8 ® under the accelerated approval pathway in the third quarter of 2026 In January 2026, Clene completed an o versubscribed registered direct offering totaling over $28 million, including an initial tranche |
| 2026-05-05 |
Clene Announces $7 Million Underwritten Offering of Common Stock
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative |
| 2026-05-05 |
Clene to Present at Upcoming May Conferences
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, |
| 2026-05-04 |
After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS
FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8 based on neurofilament light (NfL) biomarker data FDA acknowledged NfL could potentially serve as a reasonably likely surrogate endpoint Clene |
Past events
Source: https://invest.clene.com/